Wu Yongfeng, Xu Jinming, Xu Jiawei, Wang Yiqing, Wang Luming, Lv Wang, Hu Jian
1Department of Thoracic Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou, 310003 China.
2Department of Toxicology, School of Public Health, School of Medicine, Zhejiang University, Hangzhou, 310058 China.
Biomark Res. 2020 Apr 9;8:9. doi: 10.1186/s40364-020-00188-2. eCollection 2020.
High tumor mutation burden (TMB), which is associated with increased tumor immunogenicity, has been identified to predict improved response to immune checkpoint inhibitors (ICIs) therapy in non-small cell lung cancer (NSCLC). As host immunity is also significant to eliminate cancer cells, however, its clinical impact on cancer immunotherapy is still largely unknown. Here we explored the influence of age, which is an important characteristic to evaluate immune response of patients, on TMB-based predictive system for ICIs therapy in NSCLC. Our results showed that high TMB was capable of predicting better durable clinical benefit (DCB) in age group, while it was insignificant in age group. Besides, the predictive power of TMB for progression-free survival (PFS) and overall survival (OS) was better in age group than in age group. Our study illustrated that the predictive value of TMB for ICIs therapy was better in young patients than in elderly patients in NSCLC.
高肿瘤突变负荷（TMB）与肿瘤免疫原性增加相关，已被证实可预测非小细胞肺癌（NSCLC）患者对免疫检查点抑制剂（ICI）治疗的反应改善。然而，由于宿主免疫在消除癌细胞方面也很重要，其对癌症免疫治疗的临床影响仍 largely unknown 。在这里，我们探讨了年龄（评估患者免疫反应的一个重要特征）对基于TMB的NSCLC患者ICI治疗预测系统的影响。我们的结果表明，高TMB能够在年龄组中预测更好的持久临床获益（DCB），而在年龄组中则不显著。此外，TMB对无进展生存期（PFS）和总生存期（OS）的预测能力在年龄组中比在年龄组中更好。我们的研究表明，在NSCLC中，TMB对ICI治疗的预测价值在年轻患者中比老年患者更好。
